Clarity Pharmaceuticals Ltd (CLRPF)

Market Cap	771.90M
Revenue (ttm)	6.20M
Net Income (ttm)	-42.15M
Shares Out	n/a
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4,199
Open	2.120
Previous Close	2.120
Day's Range	2.120 - 2.120
52-Week Range	0.842 - 6.398
Beta	1.33
RSI	42.07
Earnings Date	Aug 22, 2025

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 69
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLRPF

Financial Performance

In 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.

Financial numbers in AUD